Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349, SHA:688505) has enrolled the first patient in the confirmatory clinical trial of its aminolevulinic acid hydrochloride granules, a Thursday filing with the Hong Kong bourse said.
The product is being tested for the visualization of non-muscular invasive bladder cancer during the transurethral resection of the bladder tumor.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments